
















Hematopoietic stem cell transplantation for neuroblastoma

Carla Nolasco Monteiro Breviglieri^{1*} , Nathália da Silva Halley Neves² , Mariana Bohns Michalowski^{3,4} , Augusto Oliveira Silva⁵ , Patrícia Shimoda Ikeuti⁶ , Ainá Henriques Melgaço⁷ , Simone de Castro Resende Franco⁶ , Cláudio Galvão de Castro Júnior^{8,9} , Adriana Seber^{1,10} 

1. Hospital Samaritano de São Paulo  – São Paulo (SP), Brazil.
2. Hospital Israelita Albert Einstein  – São Paulo (SP), Brazil.
3. Universidade Federal do Rio Grande do Sul  – Porto Alegre (RS), Brazil.
4. Hospital de Clínicas de Porto Alegre  – Porto Alegre (RS), Brazil.
5. Hospital Pequeno Príncipe – Curitiba (PR), Brazil.
6. Hospital da Criança de Brasília José Alencar – Brasília (DF), Brazil.
7. Complexo Hospitalar de Niterói – Niterói (RJ), Brazil.
8. Hemacore – São José dos Campos (SP), Brazil.
9. Certo – Guaratinguetá (SP), Brazil.
10. Grupo de Apoio ao Adolescente e à Criança com Câncer  – São Paulo (SP), Brazil.

*Corresponding author: canolasco@gmail.com

Section editor: Fernando Barroso Duarte 

Received: Sept. 14, 2025 • Accepted: Nov. 14, 2025

ABSTRACT

High-risk neuroblastoma requires intensive multimodal therapy, and autologous hematopoietic stem cell transplantation (auto-HCT) remains a key component of consolidation treatment. This consensus document updates the 2021 Brazilian recommendations for neuroblastoma transplantation, focusing on indications, eligibility criteria, conditioning regimens, and the role of single versus tandem auto-HCT. Post-transplant consolidation strategies, including radiotherapy, isotretinoin, and anti-GD2 immunotherapy, as well as transplant-related toxicities and follow-up, are reviewed. The role of transplantation in relapsed or refractory disease is also addressed. These recommendations aim to support standardized, evidence-based management of children with high-risk neuroblastoma in the Brazilian setting.

Keywords: Neuroblastoma. Stem Cell Transplantation. High-risk Disease. Pediatric. Consensus.

INTRODUCTION

Neuroblastomas are a heterogeneous group of tumors with significant clinical and biological variability, influencing their prognosis, and treatment. They are the most common extracranial solid tumor in pediatrics, accounting for 8–10% of all childhood cancers and 15% of pediatric oncology-related mortality. Approximately half of the cases present as high-risk disease, requiring intensive multimodal therapy¹.

Standard treatment for high-risk neuroblastoma (HR-NB) includes induction chemotherapy, surgical resection, and consolidation with autologous hematopoietic stem cell transplantation (auto-HCT), followed by radiotherapy and maintenance therapy with isotretinoin and anti-GD2 immunotherapy and eflornithine (DFMO). Auto-HCT plays a crucial role in reducing relapse risk, a major challenge in NB management². Immunotherapy has improved survival, but there is currently no sufficient scientific evidence to support its use instead of HCT.

Emerging approaches, such as anti-GD2 CAR-T cell therapy, have shown promising results for neuroblastoma but remain unavailable in Brazil³. Given the high relapse rate and associated mortality, strict adherence to current treatment protocols is essential. This document updates the recommendations published in the 2021 Brazilian Society of Cell Therapy and Bone Marrow Transplantation (SBTMO) neuroblastoma transplant consensus⁴ and expands on them.

The following sections focus on the consolidation phase of treatment, including auto-HCT and maintenance strategies.

INDICATIONS FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

Auto-HCT is a standard first-line consolidation therapy following induction chemotherapy and tumor resection for HR-NB, typically defined as age \geq 18 months with metastatic disease or *MYCN* gene amplification.

The best outcomes are seen when transplantation is performed in remission^{5,6}. Therefore, every effort should be made to deepen response prior to transplant, including the use of ALK inhibitors (*e.g.*, lorlatinib) in patients with *ALK* mutations and chemotherapy combined with anti-GD2 immunotherapy (chemoimmunotherapy) in those who fail to achieve a complete or very good partial response after induction⁷.

Auto-HCT may also be considered in patients with relapses after treatment, following reinduction therapy⁸.

Patients may undergo one or two consecutive HCT, depending on the recommendations of the protocol followed⁸.

Table 1 summarizes the current transplant recommendations for HR-NB, and Table 2 the eligibility criteria for autologous transplant.

Table 1. Stem cell transplantation recommendations for neuroblastoma.

Neuroblastoma	Autologous	Allogenic
First line high-risk treatment	Yes	No
Responding relapse disease	Yes	Clinical option
Mobilization failure or bone marrow residual disease	-	Clinical option

Source: Elaborated by the authors.

Table 2. Eligibility criteria for autologous transplant.

Elegibility criteria
No progressive disease (tumor increased by > 25% or new lesions)
Minimum of 2×10^6 CD34+ cells/kg per hematopoietic stem cell transplantation, ideally $> 3-5 \times 10^6$ CD34+ cells/kg*
No uncontrolled infection

Chemoimmunotherapy is the preferred treatment for persistent bone marrow involvement. If complete remission is not feasible, but other sites of disease remain stable, allogeneic transplantation may be considered, also including mobilization failure.

*Additional cells (2×10^6 CD34+ cell/kg) may be frozen for potential future needs (*e.g.*, metaiodobenzylguanidine therapy). Source: Elaborated by the authors.

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION MODALITIES AND RECOMMENDATIONS

Currently, there are two strategies to HCT: single or tandem HCT. The Children's Oncology Group (COG) demonstrated that tandem HCT using thiotepa/cyclophosphamide followed by a second HCT with carboplatin/etoposide/melphalan (CEM) 6–10 weeks later resulted in improved event-free survival (EFS) compared to single auto-HCT with CEM, when used after the COG induction regimen⁹.

However, for single auto-HCT, the International Society of Paediatric Oncology Europe Neuroblastoma Group

(SIOPEN) conducted a randomized study comparing busulfan/melphalan (BuMel) *versus* CEM after induction with rapid COJEC. The study showed improved EFS with BuMel compared to CEM⁵. It is not yet known whether one BuMel is equal or inferior to tandem.

The COG launched a multi-arm study (COG ANBL1531) in which all groups received tandem HCT, except for one arm, which received single auto-HCT with BuMel¹⁰. This single-arm cohort was discontinued due to toxicity.

Meanwhile, SIOPEN has conducted VERITAS trial, that evaluates thiotepa HCT *versus* metaiodobenzylguanidine (MIBG) therapeutic before one BuMel HCT in patients with inadequate response to induction¹¹.

These ongoing studies aim to refine consolidation strategies and optimize long-term survival outcomes for HR-NB patients.

While COG studies have demonstrated the superiority of tandem transplantation and SIOPEN is actively evaluating tandem-based strategies, it remains essential to follow the consolidation approach established by the patient's treatment protocol^{9,12}.

In Brazil, the Neuroblastoma Group continues to recommend single auto-HCT with BuMel. With the national commercialization of thiotepa, tandem transplants have become a feasible option and may be adopted following institutional discussion.

The suggested conditioning regimens are presented in Table 3.

Table 3. Suggested conditioning regimen***.

	Day -7	Day -6	Day -5	Day -4	Day -3	Day -2	Day -1	Day 0	Observations
Single BuMel	Busulfan dose per kg* in 3 hours	Busulfan dose per kg or target AUC* in 3 hours	Busulfan dose per kg or target AUC* in 3 hours	Busulfan dose per kg or target AUC* in 3 hours	24-h interval	Melphalan 140 mg/m ² in 30 min	24-h interval	PBSC Infusion (at least 2 × 10 ⁶ CD34+ cells/kg)	Mel must be infused in 15–30 min, within 1 hour of preparation
Thiotepa-Cyclophosphamide (TT-Cy) #1 (Tandem)	Thiotepa 300 mg/m ² in 2 h	Thiotepa 300 mg/m ² in 2 h	Thiotepa 300 mg/m ² in 2 h + Cy 1,500 mg/m ² in 1 h	Cy 1,500 mg/m ² in 1 h	Cy 1,500 mg/m ² in 1 h	Cy 1,500 mg/m ² in 1 h	24-h interval	PBSC Infusion (at least 2 × 10 ⁶ CD34+ cells/kg)	**
Carboplatin + etoposide + melphalan (CEM) #2 (Tandem)	Mel 60 mg/m ² + Eto (300 mg/m ²) parallel to Carbo (375 mg/m ²) over 24 h	Mel 60 mg/m ² + Eto (300 mg/m ²) parallel to Carbo (375 mg/m ²) over 24 h	Mel 60 mg/m ² + Eto (300 mg/m ²) parallel to Carbo (375 mg/m ²) over 24 h	Eto (300 mg/m ²) parallel to Carbo (375 mg/m ²) over 24 h	72-h interval			PBSC Infusion (at least 2 × 10 ⁶ CD34+ cells/kg)	Mel must be infused in 15–30 min, within 1 hour of preparation

*Dose per kg for every-24-hour busulfan administration: < 9 kg = 4 mg/kg, 9 ≤ 16 kg = 4.8 mg/kg; 16 ≤ 23 kg = 4.4 mg/kg; 23–34 kg = 3.8 mg/kg; > 34 kg = 3.2 mg/kg. Whenever available target AUC of 4,500 μMol·min/L; **TT: Bathe patients three or four times/day. Avoid large occlusive dressing and skin creams and remove adhesive residue. Cy: hydrating at 2,500–3,000 mL/m². Mesna 300 mg/m²/dose prior to each Cy dose and then 4 and 8 h after; ***Single CEM regimen consists of Melphalan 70 mg/m² for three days (30-minute infusion), etoposide 338 mg/m² for four days (continuous infusion), and carboplatin 425 mg/m² for four days (continuous infusion); PBSC: peripheral blood stem cells. Source: adapted from Ladenstein et al.⁵ and Park et al.⁹.

TRANSPLANT-RELATED COMPLICATIONS

Thrombotic microangiopathy (TMA) and veno-occlusive disease (VOD) are important toxicities after auto-HCT for HR-NB, including both single and tandem transplants. Recent multicenter data show that TMA occurred in up to 23% of patients when actively screened, and VOD in up to 19%, especially after the second HCT^{13,14}. Standardized definitions have been proposed for both toxicities^{15,16}. Given their impact on early outcomes, consistent surveillance is essential in all HCT settings.

POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION CONSOLIDATION STRATEGIES

Radiotherapy aims to improve local control. While most relapses occur in metastatic sites, local control may enhance overall survival (OS).

Primary tumor bed irradiation:

- Recommended post-HCT, especially for incompletely resected tumors;
- Timing: no sooner than D+28 and no later than D+60, before immunotherapy;
- Dose: 21 Gy to the primary site.

Metastatic sites of irradiation:

- Persistent metastasis after induction should be irradiated, but irradiating more than 50% of the bone marrow is not recommended due to hematological toxicity;
- For diffuse bone metastases, the sites of irradiation may be guided by disease reassessment after HCT⁸
- The role of radiotherapy in other metastatic sites remains unclear, and it is not routinely recommended in first-line treatment¹⁷.

Isotretinoin (Roaccutan) is a standard maintenance therapy after auto-HCT, improving EFS when used for six months¹⁸.

Start after radiotherapy, preferably between anti-GD2 cycles.

Dosage: 160 mg/m²/day, divided into two daily doses for 14 days every 28 days repeated for six months.

Toxicity: side effects include mucocutaneous dryness, hyperlipidemia, and hepatic dysfunction, requiring monitoring.

Anti-GD2 maintenance therapy post-HCT improves overall (73.2 *versus* 56.6%) and EFS (56.6 *versus* 46.1%) compared to isotretinoin alone⁶. In Brazil, the use of betadinituximabe has been approved by the Brazilian Health Regulatory Agency and was incorporated into the public health system by the National Committee for Health Technology Incorporation as maintenance post-HCT, but it does not have financial mechanism yet as of March 2025.

Start on D+60–90 days after HCT.

Dosage:

- Betadinituximabe: 10 mg/m²/day, continuous infusion for 10 days or 20 mg/m²/day in 8-hour infusion for five days, every 35 days, for five cycles.

Toxicity and management:

- Neuropathic pain is common, decreasing with subsequent cycles. Gabapentin (starting three days before infusion) plus opioids and analgesics is effective for pain control;
- Severe reactions (allergic responses, systemic inflammatory response syndrome) require clinical management;
- The first cycle under intensive care unit supervision is recommended, with subsequent cycles in a standard ward if clinically stable.

Following anti-GD2 therapy, DFMO maintenance for two years improved four-year EFS from 72 to 84%¹⁹. Its implementation in Brazil is not available yet.

RELAPSE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION

Patients who relapse after auto-HCT if respond well to salvage therapy, particularly chemoimmunotherapy, may still be eligible for a second consolidation with autologous or allogeneic HCT²⁰. Maintenance immunotherapy may also be considered.

ALLOGENEIC TRANSPLANT IN NEUROBLASTOMA

Allogeneic hematopoietic stem cell transplantation (allo-HCT) may be an option if mobilization fails or in relapsed/refractory cases^{21–23}.

Conditioning regimens (*e.g.*, Flu-Thio-Mel or Bu-Flu-Mel), graft-versus-host disease prophylaxis (*e.g.*, calcineurin inhibitors with PTCy or CSA + MTX), and post-transplant immune modulation (*e.g.*, donor lymphocyte infusions) can be used^{21,24}. KIR reactive donors may offer increased graft versus tumor effect²⁵.

Combining haploidentical HCT with anti-GD2 therapy has shown encouraging results^{21,24}. Post-transplant immunotherapy, including anti-GD2 agents, CAR-T cells, and NK cell infusion, offers promise, especially in relapsed cases, though access and side effects remain obstacles²⁶. Ongoing research aims to refine these strategies and define their role in treatment.

FOLLOW-UP SCHEDULE

Follow-up should ideally include physical examination and catecholamine measurements (VMA and HVA) every three months during the first year, every six months until year 5, and annually thereafter. Cross-sectional and functional imaging is recommended at three, six, 12, 18, 24, and 36 months after the end of therapy, and later as clinically indicated²⁷.

Long-term follow-up of at least five years is advised. Special attention should be given to the risk of thyroid dysfunction in patients who received MIBG therapy²⁸.

CONFLICT OF INTEREST

Nothing to declare.

DATA AVAILABILITY STATEMENT

All data are presented in the article.

AUTHORS' CONTRIBUTIONS

Substantive scientific and intellectual contributions to the study: Breviglieri CNM, Neves NSH, Michalowski MB, Silva AO, Ikeuti PS, Melgaço AH, Franco SCR, Castro Júnior CG and Seber A. **Conception and design:** Breviglieri CNM, Neves NSH, Michalowski MB, Silva AO, Ikeuti PS, Melgaço AH, Franco SCR, Castro Júnior CG and Seber A. **Analysis and interpretation of data:** Breviglieri CNM, Neves NSH, Michalowski MB, Silva AO, Ikeuti PS, Melgaço AH, Franco SCR, Castro Júnior CG and Seber A. **Technical procedures:** Breviglieri CNM, Neves NSH, Michalowski MB, Silva AO, Ikeuti PS, Melgaço AH, Franco SCR, Castro Júnior CG and Seber A. **Statistics analysis:** Breviglieri CNM, Neves NSH, Michalowski MB, Silva AO, Ikeuti PS, Melgaço AH, Franco SCR, Castro Júnior CG and Seber A. **Manuscript writing:** Breviglieri CNM, Neves NSH, Michalowski MB, Silva AO, Ikeuti PS, Melgaço AH, Franco SCR, Castro Júnior CG and Seber A. **Final approval:** Breviglieri CNM.

FUNDING

Not applicable.

ACKNOWLEDGEMENTS

Not applicable.

REFERENCES

1. Nong J, Su C, Li C, Wang C, Li W, Li Y, Chen P, Li Y, Li Z, She X, Yuan Z, Liu S, Chen C, Liao Q, Luo Y, Shi B. Global, regional, and national epidemiology of childhood neuroblastoma (1990-2021): a statistical analysis of incidence, mortality, and DALYs. *EClinicalMedicine*. 2024;79:102964. <https://doi.org/10.1016/j.eclinm.2024.102964>
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer myeloablative therapy and ASCT with/without anti-GD2 immunotherapy in high-risk neuroblastoma 157 group. *N Engl J Med*. 1999;341:1165–73. <https://doi.org/10.1056/NEJM199910143411601>
3. Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. *N Engl J Med*. 2023;388(14):1284–95. <https://doi.org/10.1056/NEJMoa2210859>
4. Breviglieri CNM, Michalowski MB, Gregianin L, Castro Junior CG. Hematopoietic stem cell transplantation for neuroblastoma. *J Bone Marrow Transplant Cell Ther*. 2021;2(4):136–9. <https://doi.org/10.46765/2675-374X.2021v2n4p136>
5. Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwiercz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN). Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. *Lancet Oncol*. 2017;18(4):500–14. [https://doi.org/10.1016/S1470-2045\(17\)30070-0](https://doi.org/10.1016/S1470-2045(17)30070-0)
6. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. *J Clin Oncol*. 2009;27(7):1007–13. <https://doi.org/10.1200/JCO.2007.13.8925>. Epub 2009 Jan 26. Erratum in: *J Clin Oncol*. 2014;32(17):1862–3.
7. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG Study ANBL0032. *Clin Cancer Res*. 2021;27(8):2179–89. <https://doi.org/10.1158/1078-0432.CCR-20-3909>
8. PDQ Pediatric Treatment Editorial Board. Neuroblastoma Treatment (PDQ®): Health Professional Version. 2024 Nov 12. In: PDQ Cancer Information Summaries. Bethesda: National Cancer Institute; 2002.
9. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kravaka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. *JAMA*. 2019;322(8):746–55. <https://doi.org/10.1001/jama.2019.11642>

10. Children's Oncology Group. NCT03126916: ANBL1531: Phase III Study of 131I-MIBG or ALK inhibitor therapy added to intensive therapy for children with newly diagnosed high-risk neuroblastoma. *ClinicalTrials*. 2025. Available from: <https://clinicaltrials.gov/study/NCT03126916>
11. SIOPEX. NCT03165292: VERITAS: An international multicenter phase II randomised trial evaluating and comparing two intensification treatment strategies for metastatic neuroblastoma patients with a poor response to induction chemotherapy. *ClinicalTrials*. 2025. Available from: <https://clinicaltrials.gov/study/NCT03165292>
12. SIOPEX High Risk Neuroblastoma Study 2 (HR-NBL2). *ClinicalTrials.gov* identifier: NCT04221035 [Internet]. Bethesda: U.S. National Library of Medicine; 2020. Available from: <https://clinicaltrials.gov/study/NCT04221035>
13. Hudda Z, Webster A, Anderson E, Badia P, Bagatell R, Bhar S, Bidgoli A, Boyd K, Chaudhury S, Cisneros GS, Craddock J, Davies SM, Desai AV, Drobatz L, Dvorak CC, Elkus H, Fabrizio VA, Foster JH, Fraint E, Freedman JL, Galvez J, Garcia M, Haight A, Higham C, Jodele S, Kamat A, Kaviany S, Lehmann L, Leung K, Lind KT, Llaurador G, Kapadia M, Khazal S, Massi K, Mormann M, Pater L, Rangarajan HG, Rotz S, Sabulski A, Sartain S, Schoettler ML, Sokol E, Streby KA, Stein M, Verneris MR, Weiss BD, Yazdani S, Zheng D, Dandoy CE. Acute toxicities and early outcomes of tandem autologous stem cell transplantation in pediatric high-risk neuroblastoma: a multicenter study. *Transplant Cell Ther*. 2025;S2666-6367(25)01525-8. <https://doi.org/10.1016/j.jtct.2025.10.022>
14. Yanik G. Updates on transplant for high-risk neuroblastoma. *Pediatric Session: Updates in Neuroblastoma Therapy*. In: *Tandem Meetings 2025*. 2025.
15. Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda A, Soiffer R, Vasu S. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. *Transplant Cell Ther*. 2023;29(3):151–63. <https://doi.org/10.1016/j.jtct.2022.11.015>
16. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, Dignan F, Gibson B, Guengoer T, Gruhn B, Lankester A, Locatelli F, Pagliuca A, Peters C, Richardson PG, Schulz AS, Sedlacek P, Stein J, Sykora KW, Toporski J, Trigos E, Vetteranta K, Wachowiak J, Wallhult E, Wynn R, Yaniv I, Yesilipek A, Mohty M, Bader P. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. *Bone Marrow Transplant*. 2018;53(2):138–45. <https://doi.org/10.1038/bmt.2017.161>
17. Kandula S, Prabhu RS, Nanda R, Switchenko JM, Cash T, Qayed M, Katzenstein H, Esiashvili N. Outcomes after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma. *J Pediatr Hematol Oncol*. 2015;37(3):175–80. <https://doi.org/10.1097/MPH.0000000000000264>
18. Makimoto A, Fujisaki H, Matsumoto K, Takahashi Y, Cho Y, Morikawa Y, Yuza Y, Tajiri T, Iehara T. Retinoid therapy for neuroblastoma: historical overview, regulatory challenges, and prospects. *Cancers (Basel)*. 2024;16(3):544. <https://doi.org/10.3390/cancers16030544>
19. Oesterheld J, Ferguson W, Kravaka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL. Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. *J Clin Oncol*. 2024;42(1):90–102. <https://doi.org/10.1200/JCO.22.02875>

20. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. *Pediatr Blood Cancer*. 2011;56(4):578–83. <https://doi.org/10.1002/pbc.22693>
21. Prete A, Lanino E, Saglio F, Biffi A, Calore E, Faraci M, Rondelli R, Favre C, Zecca M, Casazza G, Porta F, Luksch R, Cesaro S, Rabusin M, Parasole R, Mura RM, Lo Nigro L, Leardini D, Pagliara D, Locatelli F, Fagioli F; AIEOP-BMT Group. Phase II study of allogeneic hematopoietic stem cell transplantation for children with high-risk neuroblastoma using a reduced-intensity conditioning regimen: results from the AIEOP trial. *Transplant Cell Ther*. 2024;30(5):530.e1–e8. <https://doi.org/10.1016/j.jtct.2024.03.002>
22. Hara J, Nitani C, Shichino H, Kuroda T, Hishiki T, Soejima T, Mori T, Matsumoto K, Sasahara Y, Iehara T, Miyamura T, Kosaka Y, Takimoto T, Nakagawara A, Tajiri T; Japan Children's Cancer Group (JCCG) Neuroblastoma Committee (JNBSG). Outcome of children with relapsed high-risk neuroblastoma in Japan and analysis of the role of allogeneic hematopoietic stem cell transplantation. *Jpn J Clin Oncol*. 2022;52(5):486–92. <https://doi.org/10.1093/jjco/hyac007>
23. Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. *Bone Marrow Transplant*. 2013;48(8):1056–64. <https://doi.org/10.1038/bmt.2012.284>
24. Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, Schwarze CP, Holzer U, Lode HN, Albert MH, Gruhn B, Urban C, Dykes JH, Teuffel O, Schumm M, Handgretinger R, Lang P. Haploidentical stem cell transplantation for refractory/relapsed neuroblastoma. *Biol Blood Marrow Transplant*. 2018;24(5):1005–12. <https://doi.org/10.1016/j.bbmt.2017.12.805>
25. Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma patients' KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children's Oncology Group. *Clin Cancer Res*. 2018;24(1):189–96. <https://doi.org/10.1158/1078-0432.CCR-17-1767>
26. Qiu B, Matthay KK. Advancing therapy for neuroblastoma. *Nat Rev Clin Oncol*. 2022;19(8):515–33. <https://doi.org/10.1038/s41571-022-00643-z>
27. Children's Oncology Group. ANBL0532: Phase III randomized trial of single vs. tandem myeloablative consolidation therapy for high-risk neuroblastoma [protocol]. Version 4A. Seattle: Children's Oncology Group; 2011.
28. Clement SC, van Eck-Smit BL, van Trotsenburg AS, Kremer LC, Tytgat GA, van Santen HM. Long-term follow-up of the thyroid gland after treatment with ¹³¹I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance. *Pediatr Blood Cancer*. 2013; 60(11):1833–8. <https://doi.org/10.1002/pbc.24681>